INTRODUCTION
Cerebral vasospasm is the most serious complication of aneurysmal subarachnoid hemorrhage (SAH), in which 40% of patients experience-delayed cerebral ischemia (DCI) attributable to vasospasm, leading to infarction and thus long-term morbidity and mortality. [1, 28] The current strategy for the treatment of clinical deterioration caused by DCI includes hypervolemia, hypertension, and hemodilution (triple H), [23] or hyperdynamic therapy. [8, 19, 20] However, if symptoms are refractory to maximal medical management and vasospasm distributed diffusely to distal vasculatures, endovascular treatment such as intraarterial vasodilator infusions provides a useful invasive therapeutic option. [9] Fasudil hydrochloride is a potent vasodilator that inhibits Rho-kinase, which is involved in the development of cerebral vasospasm. Numerous findings in Japan have demonstrated the clinical effectiveness of intra-arterial fasudil infusions in inducing angiographic improvement of vasospasm and resolution of DCI with fewer adverse effects on intracranial pressure and less induction of convulsions. [5, 26] However, the real-time effectiveness of intra-arterial fasudil in reversing reduced regional cerebral blood flow (rCBF) affected by vasospasm, which may be a key to assess successful outcome of endovascular therapy, remains unclear.
We have recently introduced continuous regional cerebral hemoglobin oxygen saturation (rSO 2 ; venous-weighted % saturation of hemoglobin derived from the INVOS NIRS device) monitoring to assess the efficacy of hyperdynamic therapy in improving rCBF in the territory affected by vasospasm after SAH. [17] Here, we demonstrate the successful application of rSO 2 monitoring with multichannel near-infrared spectroscopy (NIRS) in assisting intra-arterial infusions of fasudil hydrochloride to a patient suffering from post-SAH vasospasm in the distal vascular territories. We used four-channel flexible NIRS sensors to detect rSO 2 in the vascular territories affected by vasospasm more accurately, in conjunction with systemic hemodynamic monitoring derived from a radial artery waveform-based pulse contour cardiac output device throughout the treatment period.
CASE REPORT
A 63-year-old man admitted to the stroke service at our center presented with the sudden onset of headache, vomiting, and right-sided hemiparesis followed by loss of consciousness (World Federation of Neurological Surgery grade IV). A computed tomography (CT) scan revealed diffuse thick SAH combined with a large right temporal intracerebral hematoma [ Figure 1a] , and a ruptured right middle cerebral artery aneurysm [ Figure 1b ] was successfully clipped following extensive hematoma evacuation [14] by emergent surgery performed at 6 hours after SAH onset. The early postoperative course was uneventful, and the neurological deficits disappeared with the exception of mild left hemispatial neglect. He received standard post-SAH fluid and drug management at our institution. [19, 20] On the ninth day after SAH onset, however, he became restless and then developed aphasia and right-sided hemiparesis. Transcranial Doppler (TCD) measurements were compatible with mild left middle cerebral artery (MCA) vasospasm (left MCA peak velocity, 149 cm/s; mean velocity 120 cm/s). Diffusionweighted magnetic resonance (MR) imaging performed immediately after the onset of symptoms revealed no apparent ischemic findings [ Figure 1c ], but subsequent technetium 99 m hexamethylpropyleneamine oxime single photon emission CT (Tc-99 m HMPAO SPECT) revealed a mild reduction in rCBF in the left anterior cerebral artery (ACA) and MCA territories [ Figure  1d ] indicative of clinical deterioration attributable to vasospasm. [28] Hyperdynamic therapy with dobutamine (initial dose: 3 μg/kg/min; increased in 3 μg/kg/min increments every 4 hours to a level at which the deterioration resolved) [6, 8, 17, 18] combined with mild hypervolemia with supplemental low-molecular-weight dextran (500 mL/day) [13] was initiated.
Cerebral digital subtraction angiography (DSA) was performed under local anesthesia via a transfemoral approach since there was no clinical improvement after 2 hours of maximal hemodynamic augmentation with dobutamine (12 μg/kg/min) to raise cardiac output to supranormal plateau level (cardiac index >5.0 L/min/m 2 ), assisted by radial artery waveform-based pulse contour cardiac output monitoring (FloTrac system version 3.02, Edwards Lifesciences, Irvine, CA, USA). [15, 16] Prior to DSA, transcranial rSO 2 was measured by a NIRS cerebral oximetry device (INVOS 5100C, Somanetics, Troy, MI, USA), which was composed of a light-emitting diode and two detectors located 30 and 40 mm from the diode, allowing compensation for NIR absorption from the scalp and the skull to determine rSO 2 in the underlying area of the brain. Each of the four-channel sensors (SAFB-SM, Somanetics, Troy, MI, USA) was placed symmetrically on the scalp of the patients at the approximate location overlying the spasm-affected vascular territory and on the mirror--image location in the opposite hemisphere. [17] DSA revealed severe vasospasm of the distal portion of the A1 segment of the left ACA and of the proximal left A2 and M2 segments and diffuse spasm in their branches [ Figure 2a ]. After systemic heparinization, a 5-Fr. guiding catheter was advanced to the cervical portion of the internal carotid artery and a microcatheter was placed at the top of the internal carotid artery [ Figure 2b , Arrow] and fasudil hydrochloride (25 mg) was infused at a rate of 1.0 mg/mL (consisting of 60 mg of fasudil hydrochloride mixed in 60 mL of normal saline) for distribution into both the ACA and MCA territories, resulting in significant reversal of vasospasm in distal A1 and M1 segments [ Figure 2c ] and improvement of cerebral circulation time (as measured by the interval between the first image in which contrast is visible above the supraclinoid internal carotid artery and the peak filling of the cortical parietal veins) [11] from 6.6 to 5.3 seconds. Since focal severe vasospasm still existed in the distal potion of M3 (superior division), superselective infusion of fasudil (25 mg Repeated DSA demonstrated moderate vasospasm of the distal A1 and diffuse vasospasm in the distal ACA and MCA branches as well as persistent focal spasm in the distal potion of the M3 segment [ Figure 3c ]. Then intraarterial fasudil infusions (25 mg/each) were performed again, resulting in improvement of the distal vasospasm and cerebral circulation time [ Figure 3c , d, inset] from 5.8 to 4.9 seconds. In response to intra-arterial fasudil infusions, rSO 2 in the left ACA--MCA territory rapidly increased to a level close to that on the contralateral side [ Figure 3e ]. The patient's symptoms gradually resolved hyperdynamic therapy by titration of dobutamine dose and intravenous calcium antagonists. [19, 20] No apparent periprocedural clinical/vital signs or radiological findings of increased intracranial pressure or hemorrhage associated with the intra-arterial fasudil therapy were observed. Follow-up MR angiography on day 14 (corresponding to 3 days after the second endovascular therapy) confirmed improvement of vasospasm [ Figure 4a ]. Diffusionweighted MR imaging revealed no additional ischemic findings after repeated endovascular therapy [ Figure 4b ]. Abnormal rCBF distributions in the left hemisphere were also normalized [ Figure 4c ]. The patient underwent ventriculoperitoneal shunt placement on day 30 for the treatment of post-SAH normal pressure hydrocephalus [ Figure 4d ], resulting in favorable functional outcome with a modified Rankin Scale score of 1 at 2 months.
DISCUSSION
Monitoring of cerebral autoregulation from a focal brain region using direct brain tissue oxygenation measurement has been shown to be of prognostic value in patients with SAH. [7] As observed in this case, NIRS but not TCD successfully tracked real-time hemodynamic changes in a specific brain region coinciding with neurological deterioration and findings from imaging studies (MRI and SPECT) following intra-arterial fasudil therapy. Currently, TCD is a widely available and highly affordable noninvasive technique for screening of vasospasm; however, it may not necessarily assist in the identification of focal ischemia or monitoring treatment effects because of its poor sensitivity in detecting distal M1 and M2 vessel vasospasm. [24, 25] One important factor responsible for the , systolic blood pressure (< 180 mmHg), and heart rate (< 130 bpm) were also maintained within each target for discrepancy between NIRS and TCD measurements may be the area of interest for assessment of CBF changes. With TCD, only the CBF of the brain supplied by the blood flow of MCA is usually monitored, while the NIRS rSO 2 reflects changes in cerebral blood oxygenation where the flexible sensor can be placed. Since continuous rCBF monitoring using thermal diffusion flowmetry implanted into the brain tissue is more effective for intra-arterial papaverine therapy than TCD in reversing vasospasm, [27] noninvasive NIRS may also be an alternative CBF-based neuromonitoring strategy.
Our findings indicate the importance of appropriate NIRS sensor location determined by exploring the vascular territory affected by vasospasm for accurate determination of rSO 2 changes over time. In a recent study of rSO 2 readings using the INVOS device, however, no clear trends in rSO 2 change associated with intraarterial vasodilator therapy for angiographic vasospasm were detected. [21] On the other hand, there are also reports suggesting that rSO 2 may enhance reliability in detecting focal cerebral ischemia [4, 22] or be useful for assessing the therapeutic effectiveness of intra-arterial papaverine therapy for severe symptomatic vasospasm after SAH. [12] We believe that such discrepancies may simply be due to recording only from the forehead space over the ACA/ MCA watershed area with two-channel sensors, which may thus have lost the specific areas of interest where vasospasm impaired microcirculatory autoregulation.
Intra-arterial fasudil infusion is an effective modality for treating vasospasm after SAH. It is important to note that the vasodilative effect of fasudil hydrochloride is transient and temporary and that approximately 40% of patients required multiple treatments for recurrent vasospasm, despite angiographic improvement in 86-100% and clinical improvement in 44-82% of cases. [26] A decrease in focal rSO 2 readings in the treated territories preceded by clinical deterioration may, as shown in this case, be a warning sign necessitating further investigation. Systemic blood pressure depression (> 20 mmHg) [26] and convulsions (12.9%) [5] have been reported as adverse effects of intra-arterial fasudil therapy. We tried to avoid such serious risks by application of continuous hemodynamic monitoring with a less-invasive device and use of the recommended constant rate of fasudil delivery (< 3 mg/min) with an infusion pump.
Application of NIRS to detecting and managing vasospasm has several pitfalls and limitations. The quality of NIRS measurements can potentially be restricted by polycythemia, and the increased area of the cerebrospinal fluid layer. [10, 30] The four-channel flexible and thin NIRS sensors in the current INVOS device enables close skin contact for longer periods of time and more stable monitoring than with any other available NIRS probes; however, it should be kept in mind that the method of analysis using continuous-wave light NIRS reflects O 2 delivery by providing an accurate, venous-weighted measure of hemoglobin saturation in the tissues beneath the sensors [2] but does not provide quantitative measurement of hemoglobin concentrations as demonstrated by time-resolved or frequency-domain NIRS. [3, 29] It is also important to note that the nearinfrared light penetrates 2.0-2.5 cm into the head and hence interrogates only the cortical regions and not deeper brain structures. Further studies to determine criteria for selecting patients are warranted when this bedside monitoring is more effective in monitoring treatment of vasospasm with intra-arterial fasudil infusions.
In conclusion, this case illustrates the value of multichannel NIRS to assist intra-arterial fasudil therapy in detecting and treating diffuse/distal vasospasm in selected situations such as when serial TCD monitoring is ineffective. Further studies in a larger study population are needed to reflect better clinical outcome with this monitoring strategy.
